Clinical trials: Disseminated Fungal Infection
Breast Cancer, Chronic Myeloproliferative Disorders
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
RATIONALE: A donor stem cell transplant can lower the body's immune system, making it difficult to fight off infection. Giving antibiotics, such as moxifloxacin, may help prevent bacterial infections in patients who have recently…
- Conditions
- Breast Cancer, Chronic Myeloproliferative Disorders, Gestational Trophoblastic Tumor, Infection
- Trial name
- NCT00324324
- Testing
- moxifloxacin hydrochloride
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- OHSU Knight Cancer Institute
Invasive Fungal Infection
Voriconazole Trough Plasma Levels : Genetic Polymorphism, Efficacy, Safety in Patients With Hematologic Malignancy
Multiple factors are associated with a large variability in voriconazole exposure following standard dose administration, such as non-linear saturable pharmacokinetics, drug-drug interactions, liver disease, patient age, and…
- Trial name
- NCT01148160
- Testing
- voriconazole
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- Asan Medical Center
Mycoses
Emergency Use of Voriconazole in Patients With Life-Threatening Invasive Fungal Infections
This protocol provides for emergency treatment with the experimental anti-fungal drug voriconazole for patients with life-threatening invasive fungal infections.
- Trial name
- NCT00015665
- Testing
- Voriconazole
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Invasive Fungal Disease, Critical Illness
De-escalation - Antifungal Treatment Immunocompromised Patients
A small proportion of intensive care unit patients receiving antifungals have a proven invasive fungal infection. However, antifungal treatment has side effects such as toxicity, emergence of resistance, and high cost.
- Trial name
- D-ATFIM (NCT03774316)
- Where
- France
- Volunteers
- 275 people
- Sponsor
- University Hospital, Lille
Invasive Pulmonary Aspergillosis, Chronic Obstructive Pulmonary Disease
Efficacy and Safety of Caspofungin for Invasive Pulmonary Aspergillosis Underlying Chronic Obstructive Pulmonary Disease
The investigators propose to study the efficacy and safety of three-week antifungal therapy with caspofungin in hospitalized patients with proven or probable IPA underlying chronic obstructive pulmonary disease.
- Trial name
- NCT01499433
- Testing
- caspofungin
- Where
- China
- Volunteers
- 40 people
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
Mycoses, Candidiasis, Invasive
Oral Ibrexafungerp (SCY-078) vs Standard-of-Care Following IV Echinocandin in the Treatment of Invasive Candidiasis
The purpose of this study is to compare the safety, pharmacokinetics, and efficacy of oral SCY-078 vs. standard-of-care following initial intravenous echinocandin therapy in the treatment of invasive candidiasis.
- Conditions
- Mycoses, Candidiasis, Invasive, Candidemia
- Trial name
- NCT02244606
- Testing
- SCY-078, Fluconazole, Micafungin
- Where
- 30 sites in United States, El Salvador and 3 more
- Volunteers
- 27 people
- Sponsor
- Scynexis, Inc.
Candidiasis, Aspergillosis
Acetato de Caspofungin (Cancidas®) in the Treatment of Fungal Infection
We wanted to determine the efficacy and the safety of caspofungin acetate (CANCIDAS®) in the treatment of invader fungal infection (IFI) specifically, Invasive Candidiasis (CI) in adults patients without neutropenia and Invasive…
- Trial name
- NCT00388167
- Testing
- Caspofungin
- Where
- 27 sites in Spain
- Volunteers
- 320 people
- Sponsor
- PETHEMA Foundation
Invasive Fungal Infections
Population Pharmacokinetics and Dose Optimization of Caspofungin in Adolescents
Caspofungin (CAS) is used to prevent and treat invasive fungal infections patients older than 3 months. However, the optimal dosing strategy of CAS is lacking in adolescents from 12 to 17 years old, especially those undergoing…
- Trial name
- NCT05881109
- Testing
- Caspogunfin
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Shandong University
Candidiasis
Comparison of Two Treatments to Prevent Invasive Fungal Infections in Patients Who Have Received Liver Transplants
The purpose of this study is to compare the safety and effectiveness of 2 treatments to prevent invasive fungal infections (IFI), which are infections caused by yeasts and molds that are common in patients with weak immune…
- Trial name
- NCT00001107
- Testing
- Fluconazole, AmBisome
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Ventilator Associated Pneumonia, Pulmonary Aspergillosis Invasive
Incidence of Invasive Pulmonary Aspergillosis in Ventilator-associated Pneumonia
Mechanically ventilated patients are at risk of developing ventilator-associated pneumonia (VAP). Invasive pulmonary aspergillosis (IPA), the diagnosis of which motivates the implementation of specific treatments, is one of the…
- Trial name
- ASPIC (NCT05671328)
- Testing
- Biological examinations performed on blood and BAL
- Where
- France
- Volunteers
- 263 people
- Sponsor
- University Hospital, Lille
Invasive Pulmonary Aspergillosis
Evaluation of Exhaled Breath Condensate in the Diagnosis of Invasive Pulmonary Aspergillosis
The purpose of this study is to evaluate the diagnostic potential of biomarkers for invasive pulmonary aspergillosis in exhaled breath condensate.
- Trial name
- NCT01247142
- Where
- Belgium
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Candidemia
Detecting Infections Rapidly and Easily for Candidemia Trial (DIRECT)
The purpose of this study is to assure the uniform collection, handling, storage and transport of patient whole blood specimens and associated information to support validation of the T2 Candida Assay.
- Trial name
- DIRECT (NCT01525095)
- Where
- 5 sites in United States
- Volunteers
- 700 people
- Sponsor
- T2 Biosystems
Enterobacterial Infections, Oncologic Disease
Biodistribution and Pathophysiology Study of 18F-Fluorodeoxysorbitol (18F-FDS) in Diseased Patients
In this study, the investigators will assess the hypothesis that this new positron emission tomography (PET) radiopharmaceutical, 18F-Fluorodeoxysorbitol (18F-FDS), will specifically localize at sites of Gram-negative bacterial…
- Conditions
- Enterobacterial Infections, Oncologic Disease, Inflammatory Disease, Invasive Fungal Infections
- Trial name
- NCT05611892
- Testing
- 18F-FDS PET/CT
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Johns Hopkins University
HIV Infections, Histoplasmosis
A Study of Itraconazole in the Treatment and Prevention of Histoplasmosis, a Fungal Infection, in Patients With AIDS
To evaluate the feasibility of itraconazole as (1) primary therapy in histoplasmosis and (2) maintenance therapy after completion of primary therapy. To evaluate the effect of therapy of CNS histoplasmosis.
- Trial name
- NCT00000975
- Testing
- Itraconazole
- Where
- 12 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Invasive Fungal Infections
A Retrospective Study Evaluating the Efficacy and Safety of Micafungin Sodium in the Treatment of Invasive Fungal Infections
The objective of this study is to evaluate the efficacy of intravenous micafungin for the empirical antifungal therapy, pre-emptive antifungal therapy, diagnostic driven antifungal therapy or targeted antifungal therapy patients…
- Trial name
- NCT02678598
- Testing
- Micafungin
- Where
- 17 sites in China
- Volunteers
- 2,555 people
- Sponsor
- Astellas Pharma China, Inc.
Mucorales Infection, Mucormycosis
Biomarkers for Invasive Mucormycosis
Mucormycosis (MM) is one of the main invasive fungal infection (IFI), and is determined by filamentous fungi belonging to the order of Mucorales, with a mortality rate ranging from 20 to 60% according to localization.
- Trial name
- BIM (NCT05406037)
- Testing
- Venous sample
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University Hospital, Lille
Invasive Pulmonary Aspergillosis
Prophylaxis of Fungal Invasive Infections in Leukemia
To assess the overall clinical yield - in terms of efficacy and safety endpoints of adding caspofungin as prophylaxis of Invasive Pulmonary Aspergillosis in patients undergoing induction treatment for newly diagnosed acute…
- Trial name
- PROFIL-C (NCT00501098)
- Testing
- Caspofungin
- Where
- 8 sites in Italy
- Volunteers
- 100 people
- Sponsor
- Northern Italy Leukemia Group
Acute Myeloid Leukemia
Intermittent Liposomal Amphotericin B Primary Prophylaxis
The purpose of this trial is to see which dose of liposomal amphotericin B is the safest when used as a preventer against invasive fungal infection in patients with acute leukaemia who are undergoing chemotherapy.
- Trial name
- NCT00451711
- Testing
- Liposomal amphotericin B
- Where
- 2 sites in Australia
- Volunteers
- 60 people
- Sponsor
- Bayside Health
Cancer
Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant
RATIONALE: Methotrexate and glucocorticoid therapy, such as prednisone or methylprednisolone, may be an effective treatment for acute graft-versus-host disease caused by a donor stem cell transplant.
- Trial name
- NCT00357084
- Testing
- methotrexate, methylprednisolone, prednisone
- Where
- United States
- Volunteers
- 53 people
- Sponsor
- Fred Hutchinson Cancer Center
Invasive Fungal Disease, Chronic Disseminated Candidiasis
Hepatosplenic CANdidiasis : PETscan and Immune Response Analysis
The purpose of this study is to determine whether F18 fluorodeoxyglucose (18F-FDG) positron-emission tomography scan (PET scan) is useful for the therapy strategy of hepatosplenic candidiasis.
- Conditions
- Invasive Fungal Disease, Chronic Disseminated Candidiasis, Hematological Malignancies, Hematopoietic Stem Cell Transplantation
- Trial name
- CANHPARI (NCT01916057)
- Testing
- 18F-FDG PET Scan
- Where
- France
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Assistance Publique - Hôpitaux de Paris